RxDoctor Payments Data

Shari Anthony

Family Medicine · St Petersburg, FLNPI 1447697099

Payments from drug & device makers

$4,457in general payments, 2019–2025

Across 182 payments — averaging $24.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$739
  • Novo Nordisk$697
  • AbbVie$627
  • Boehringer Ingelheim$318
  • Johnson & Johnson$299
  • Lilly USA, LLC$243
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,435100%
  • Education$80%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,457 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$28,262
Medicare patients
88
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$66,302
EliquisApixaban13$21,799
XareltoRivaroxaban19$17,343
MounjaroTirzepatide14$15,053
Repatha SureclickEvolocumab12$6,752
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,167
Albuterol Sulfate HfaAlbuterol Sulfate47$1,920
Levothyroxine Sodium191$1,765
Atorvastatin Calcium215$1,600
Nifedipine ErNifedipine32$1,295
Ultra-Fine Short Pen NeedlePen Needle, Diabetic20$1,210
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine28$1,022
Ventolin HfaAlbuterol Sulfate17$962
Lisinopril153$962
Montelukast Sodium55$934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$697$66,30246 claims
PfizerEliquis$192$21,79913 claims
Johnson & JohnsonXarelto$299$17,34319 claims
Lilly USA, LLCMounjaro$243$15,05314 claims
AbbVieSynthroid$627$56011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →